Physician profile
Maureen E Eisenberg
NPI 1336148121
$10,806.44
in general payments reported to CMS, 2019-2025
46 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $1,163 · 2021: $1,539 · 2022: $1,728 · 2023: $1,833 · 2024: $1,755 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,218 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,217.85 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,755.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,206.89 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,192.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.84 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $708.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $650.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $629.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $577.52 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Astellas Pharma US INC | $289.50 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $238.93 | 2019-2025 | Evenity, Prolia, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $235.40 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.80 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $214.95 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $213.24 | 2020-2025 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.20 | 2024-2025 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.